Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00366444 · ClinicalTrials.gov registry record · Phase 3
Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery
A Phase 3 study, sponsored by Xanodyne Pharmaceuticals.
- Completed
- Registry status
- Phase 3
- Development phase
- 201
- Enrollment target
NCT00366444 is a Phase 3 study that has completed, run by Xanodyne Pharmaceuticals. The registered enrollment target is 201 participants.
The verdict
NCT00366444, a Phase 3 study, has completed, sponsored by Xanodyne Pharmaceuticals.
- COMPLETED
- Registry status
- Phase 3
- Development phase
- 201 participants
- Enrollment target
Study Summary
A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.
Interventions
- DRUG Placebo
- DRUG diclofenac potassium (XP21L)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 201 participants |
| Start Date | 2006-08 |
| Phase | Phase 3 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00366444
The ClinicalTrials.gov registry entry for NCT00366444 describes a study currently listed as completed, categorized as Phase 3. The registered enrollment target is 201 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Xanodyne Pharmaceuticals, which has 4 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 2 interventions - of which Placebo is the first listed.
NCT00366444 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00366444 about?
NCT00366444 is a clinical study titled "Multicenter Study to Evaluate the Analgesic Efficacy of XP21L in Subjects With Pain Following Bunionectomy Surgery". A multicenter study to evaluate the analgesic efficacy of XP21L in subjects with pain following bunionectomy surgery.
What is the current status of trial NCT00366444?
This trial is currently completed. It is a Phase 3 study. The enrollment target is 201 participants. The study started on 2006-08.
What interventions are being tested in trial NCT00366444?
The interventions under investigation include: Placebo (DRUG), diclofenac potassium (XP21L) (DRUG).
Who is sponsoring clinical trial NCT00366444?
This trial is sponsored by Xanodyne Pharmaceuticals, which has 4 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.